Pathological similarities between low birth weight-related nephropathy and nephropathy associated with mitochondrial cytopathy by Toshiyuki Imasawa et al.
Imasawa et al. Diagnostic Pathology 2014, 9:181
http://www.diagnosticpathology.org/content/9/1/181RESEARCH Open AccessPathological similarities between low birth
weight-related nephropathy and nephropathy
associated with mitochondrial cytopathy
Toshiyuki Imasawa1,2*, Masashi Tanaka3, Naoki Maruyama4, Takehiko Kawaguchi1, Yutaka Yamaguchi5,
Rodrigue Rossignol6, Hiroshi Kitamura2 and Motonobu Nishimura1,2Abstract
Background: Individuals born with a low birth weight (LBW) have a higher risk of developing kidney dysfunction
during their lifetime and sometimes exhibit focal segmental glomerulosclerosis (FSGS) lesions in their glomeruli. We
herein try to obtain other pathological characteristics of LBW-related nephropathy.
Methods: We retrospectively evaluated the renal pathology of four patients demonstrating FSGS with a history of
LBW. Two mitochondrial cytopathy patients were also analyzed. DNA mutations were surveyed using a
PCR-Luminex assay.
Results: In all four FSGS patients with a history of LBW, focal segmental glomerulosclerosis were detected.
Interestingly, granular swollen epithelial cells (GSECs), which have previously been reported exclusively in patients
with mitochondrial cytopathy, were also observed in the distal tubules and/or collecting ducts of all four patients
with a history of low birth weight in this study. Electron microscopy revealed that these granular swollen epithelial
cells included an increased number of enlarged mitochondria. Furthermore, cytochrome c oxidase subunit IV
staining of patients with a history of low birth weight and patients with mitochondrial DNA mutations showed
unbalanced expression patterns in glomeruli and a part of tubular cells. However, no mitochondrial gene mutations
were detected in any of our four patients with low birth weight-related nephropathy.
Conclusions: This is the first report to show the pathological similarities not only in glomeruli but also tubuli
between nephropathy with a LBW history and nephropathy with mitochondrial cytopathy.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_181
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Low-birth-weight (LBW) is also associated with an in-
creased risk of end-stage renal disease (ESRD) [1]. Studies
of both humans and animals have shown LBW to be sig-
nificantly associated with a decreased number of nephrons
[2-4]. Brenner proposed the glomerular hyperfiltration
theory in which adaptive mechanisms activated in* Correspondence: imasawa@cehpnet.com
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unless otherwise stated.response to nephron loss increases the capillary pressure
and the incidence of glomerular hypertrophy [5,6]. This
intraglomerular hypertension results in accelerated dam-
age to nephrons with further nephron loss. This vicious
cycle promotes the further progression of chronic kidney
disease (CKD).
In particular, it is well known that representative glom-
erular changes in LBW individuals include focal segmental
glomerulosclerosis (FSGS) [7]. Although intraglomerular
hypertension is associated with the pathogenesis of FSGS,
the clear mechanisms by which FSGS lesions are formed
have not been clarified. Because detail pathological ana-
lysis sometimes gives a clue to assess the pathogenesis, weal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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order to obtain more detail pathological characteristics.
Methods
Patients
From January 2006 to December 2011, we performed
472 kidney biopsies in our division. In these cases, there
were four cases of FSGS among patients born with a
birth weight under 2,500 g (according to the WHO
definition of LBW). These four patients (LBW 1–4) were
retrospectively evaluated pathologically and genetically.
In addition, two patients (Mt 1 and 2) who were found
to have mitochondrial DNA (mtDNA) mutations and
underwent kidney biopsies to investigate the cause of
their proteinuria were also evaluated. As normal controls
for staining (N = 3), kidneys dissected because of kidney
cancer were used.
Histological analysis
Briefly, kidney specimens fixed in 10% neutral buffer for-
malin followed by embedding in paraffin were used for a
light microscopy analysis with routine staining, as fol-
lows: hematoxylin and eosin (HE), periodic acid-Schiff
(PAS), Masson’s trichrome stain and periodic acid-
methenamine-silver (PAM)-HE stain. The kidney spec-
imens used for the electron microscopy analysis were
fixed in 2% glutaraldehyde (pH 7.3-7.4) followed by 2%
osmium tetroxide (pH 7.3-7.4). For cytochrome c oxi-
dase subunit IV (COX IV) staining, paraffin-embedded
specimens were used. Following deparaffinization and
antigen activation using 10 mM of boiled citrate buffer
(pH 6.0), rabbit anti-COX-IV antibodies (clone 3E11)
(Cell Signaling Technology, Inc., Danvers, MA) were
used as the primary antibody. SignalStain® Boost IHC
Detection Reagent (HRP, Rabbit) (Cell Signaling Tech-
nology, Inc.) was used to detect the rabbit primary
antibody, according to the manufacturer’s instructions.
Assay for detecting mitochondrial gene mutations
Blood samples (1 ml/each analysis) were collected in
EDTA-2Na tubes. Following centrifugation, the pellets
were used for the analysis. For the analysis of urine sedi-
ments, over 100 ml of urine was collected from each pa-
tient, and the pellets obtained after centrifugation were
used for the analysis. Five slices (4 μm) of frozen kidney
sections were used for the genetic analysis. A PCR-
Luminex assay, which can be used to survey 61 different
pathogenic mtDNA mutations, was performed according
to our previously reported method [8].
Ethical considerations
This study was conducted in accordance with the “Ethical
Guidelines for Clinical Studies” (Revised on December 28,
2004, Ministry of Health, Labour and Welfare of Japan).All medical professionals involved in this study were
required to comply with these ethical standards. The local
Ethics Committee of Chiba-East Hospital approved the
study protocol (No. 22), and all subjects provided their
informed consent to participate in this study.
Results
All four LBW-related nephropathy patients exhibited
perihilar variants of FSGS in their glomeruli
The background characteristics of the patients are sum-
marized in Table 1. All four LBWN patients underwent
kidney biopsies in order to determine the etiology of their
persistent proteinuria. All four LBWN patients were male,
with a mean birth weight of 1,692 g. The gestational ages
and the reasons for the low birth weight could not be fully
assessed in these cases (The gestational age of LBW1 was
28 weeks and that of LBW2 was 38 weeks). No subjects
had symptoms of myopathy or encephalopathy, a history
of stroke-like episodes or difficulty hearing. Although all
patients had no subjective symptoms, they were found to
have proteinuria on periodic medical examinations. Only
one (LBW 3) of the LBWN patients suffered from diabetes
mellitus (with a five-year history). The kidney size tended
to be smaller than normal, except in LBW 3 (Table 1).
The light microscopy analysis revealed that the glomeruli
of all LBWN patients exhibited FSGS (Figure 1). Patient
Mt 1 was initially found to have proteinuria at 39 weeks of
gestation and was subsequently referred to our hospital
because the proteinuria persisted for one year after delivery.
Although she had no symptoms of MELAS (mitochondrial
myopathy, encephalopathy, lactic acidosis, stroke-like epi-
sodes), we found increased morphologically abnormal
mitochondria in her podocytes (Figure 2A). Therefore, we
evaluated her mtDNA at our hospital and detected an
mtDNA mutation (3243 A >G). Patient Mt 2 was found to
have proteinuria on a periodic medical checkup at 19 years
of age. She also had no symptoms of MELAS. She refused
an assessment of her serum lactate level. However, she
had a brother with MELAS (3243 A >G), and a kidney
biopsy revealed that her podocytes included increased
mitochondria (data not shown). Her mtDNA mutation
(3243 A >G) was diagnosed at another hospital. Although
the characteristic glomerular change in patients with mito-
chondrial cytopathy is FSGS, as previously described in
several reports [9-11], neither of our two patients with
mtDNA mutations had apparent FSGS lesions in the eval-
uated glomeruli (data not shown). An electron microscopy
analysis of the two patients with mtDNA mutations re-
vealed that the glomerular epithelial cells contained an
increased number of enlarged mitochondria and mild foot
process effacement. On the other hand, we found no mor-
phological abnormalities or increments in the number of
mitochondria in any of the observed sections obtained
from the LBWN patients (Figure 2B-D). However, the
Table 1 Summary of patients



























LBW1 21 M 22.0 978 120/65 98 0.34 15.2 880 24 8.3 16.7 + + none
LBW2 20 M 21.0 1900 126/82 46 0.56 n.d. 848 4 0 25 + + none
LBW3 36 M 31.2 1400 125/75 74 1.35 n.d. 1208 14 42.9 7.1 + + none
LBW4 41 M 24.5 2465 121/70 63 0.83 15.8 988 20 15 10 + + none
Mt1 34 F 17.6 2720 115/63 48 0.29 9.1 936 11 45.5 0 - + 3243 A>G
Mt2 28 F 17.5 3630 96/63 118 1.39 n.d. 953 16 0 0 - + 3243 A>G
1BMI, body max index at the time of kidney biopsy.
2BP, blood pressure: BP at the time of kidney biopsy is expressed as systolic/diastolic.
3eGFR, estimated glomerular filtration: eGFR is calculated by Japanese GFR equation [12] from serum creatinine value, age, and sex at the kidney biopsy.
4The data of urinary protein is based on a urinalysis on the day of the kidney biopsy.
5Serum lactate is measured by an enzymatic assay (normal range: 3-17mg/dl). We did not measure the lactate values in three of six patients (expressed as “n.d.”).
6The long axis of the left kidney was measured by an echogram just before the kidney biopsy.
7The rate of the number of globally sclerosed glomeruli/total glomeruli in the observed section is expressed.
8 The rate of the number of segmentally sclerosed glomeruli/remnant glomeruli (total glomerular number minus GS glomeruli) is expressed.
9The existence of glomerular hypertrophy is defined when the diameter of capillary area is over 250μm [13].



















Figure 1 Representative photos of glomeruli in the FSGS patients born with LBW. (A): Exudative and sclerotic lesions are indicated in the
perihilar area by arrows (LBW 1, PAM-HE stain). (B): Segmental sclerosis in the perihilar area is indicated by the arrow (LBW 2, Masson’s Trichrome stain).
(C): Segmental sclerosis is indicated by the arrow (LBW 3, Masson’s Trichrome stain). (D): Segmental sclerosis in the perihilar area is indicated by the
arrow (LBW 4, PAS stain).
Imasawa et al. Diagnostic Pathology 2014, 9:181 Page 4 of 9
http://www.diagnosticpathology.org/content/9/1/181podocytes of the four LBWN patients showed mild foot
process effacement (Figure 2B-D), similar to that observed
in the patients with mtDNA mutations (Figure 2A).
All four patients with LBW-related nephropathy and the
two patients with mtDNA mutations had granular swollen
epithelial cells in their collecting ducts or distal tubules
The presence of granular swollen epithelial cells (GSECs)
in the collecting ducts or distal tubules was recently
reported to be a characteristic pathological change in pa-
tients with mitochondria cytopathy [14]. All four patients
with LBWN as well as the two patients with mtDNA mu-
tations had GSECs in their collecting ducts and/or distal
tubules (Figure 3A-F). In addition, a portion of these
GSECs had dropped out of the arrangement of the tu-
bules. The electron microscopy analysis revealed that
these GSECs contained an increased number of enlarged
mitochondria (Figure 3G, H), and the nuclei occasionally
seemed to be condensed.The expression of Complex IV exhibited a mosaic pattern
of staining in the glomeruli and tubules of both the
LBW-related nephropathy patients and mtDNA
mutation patients
Complex IV, which is composed of 13 subunits, is the
terminal of the electron transfer chain in mitochondria.
It was reported that the complex IV activity of podocytes
changes in pathological conditions [15]. Therefore, we
here stained for COX IV, which is one of the subunits. A
COX IV expression analysis of normal controls showed
that podocytes should be almost equally positive in the
glomerulus (Figure 4A) and that tubular cells are also
equally positive at the same luminal level (Figure 4B).
However, in the LBWN patients, the expression of COX IV
in the podocytes was unbalanced. Only a few podocytes
appeared to intensely express COX IV, although the others
expressed less COX IV (Figure 4C, E). In addition, the
COX IV staining in a part of tubules of the LBWN patients
exhibited a mosaic pattern, even at the same luminal level
AC D
B
Figure 2 Electron microscopy of the glomeruli. (A): In Mt 1, a glomerular podocyte (indicated by the arrow) exhibits an increased number of
mitochondria. The podocytes show patchy foot process effacement (arrowheads). (B-D): In LBW 1 (B), LBW 2 (C), and LBW 3 (D), the number and
morphology of mitochondria in the glomerular podocytes are normal. However, the podocytes show patchy foot process effacement (arrowheads).
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appeared to correspond to GSECs. The expression patterns
both of the glomerular podocytes and tubules in the
patients with mtDNA mutations showed a mosaic pattern
(Figure 4G, H), similar to that observed in the LBWN
patients. The degree of the mosaic patterns in glomeruli
and tubular cells should be more intense in patients with
mtDNA mutations compared with LBWN patients.
The LBW-related nephropathy patients did not have any
mitochondrial gene mutations
According to the PCR-Luminex assay, none of the 61
mtDNA mutations were detected in the blood, urine or
kidney sections of the four LBWN patients (Table 1).
However, an mtDNA mutation (3243 A > G) was clearly
detected in all samples of blood, urine sediment and
kidney sections in patient Mit 1. Because another patient
(Mit 2) had already been found to have 3243 A > G
mtDNA at another hospital, we did not perform an
mtDNA mutation analysis using RCR-Luminex due to
ethical considerations.Discussion
Table 2 presents a summary of our results. The character-
istic feature of glomerular involvement observed in pa-
tients with mitochondrial cytopathy is focal segmental
glomerulosclerosis (FSGS), as previously described in a
considerable number of reports [9-11]. In addition, it was
recently reported that the presence of granular swollen
epithelial cells (GSECs), in which enlarged mitochondria
increase, in the distal tubules or collecting ducts is a spe-
cific pathological change in patients with mitochondrial
cytopathy [14]. On the other hand, adults born with LBW
have a high risk of kidney damage [1,16] and sometimes
exhibit FSGS lesions in their glomeruli [7]. In this report,
we showed that the pathological findings of kidney biopsy
specimens were similar between patients with mtDNA
mutations and those with LBWN with respect to the
following three points (Table 2): 1. glomerular changes
involve the presence of FSGS lesions and podocytes with
foot process effacement; 2. a portion of tubular cells dis-
play characteristics of GSECs, in which the number of en-





Figure 3 (See legend on next page.)
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Figure 3 Photos of tubules in patients of LBW-related nephropathy and patients with mtDNA mutation; (A)-(F): Masson’s Trichrome
stain, (G) and (H): electron microscopy (original magnification: × 3000). GESCs are present in collecting ducts or distal tubules of LBW 1
(A), LBW 2 (B), LBW 3 (C), LBW 4 (D), Mt 1 (E), and Mt 2 (F). In LBW 4 (G), the number of mitochondria with morphological abnormalities is
increased in the collecting duct. One nucleus appears to be condensed. In Mt 2 (H), increased mitochondria are also observed in the
cytoplasm of collecting duct.
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portion of podocytes and tubular cells. In fact, although
our two patients with mtDNA mutations had no FSGS
lesions, there is a possibility of sampling error. As another
possibility, because these two patients had no other symp-
toms of mitochondrial cytopathy, the glomerular lesions
could be slight. Furthermore, although we evaluated 5
obesity-related nephropathy with FSGS lesions (all patients
are under 40-year-old), there were no GSECs.
Because the presence of GSECs in the tubules was previ-
ously described to be an exclusive characteristic change in
patients with mitochondrial cytopathy (12), we initially
suspected that the four patients with LBWN had certain
mtDNA mutations. However, based on the PCR-Luminex
method [8], which can be used to detect 61 different
pathogenic mtDNA mutations, no mtDNA mutations were
detected in the blood, urine sediment or kidney sections of
the four patients with LBWN. Although these 61 mtDNA
mutations include most mtDNA mutations previously
reported in Japan [8], we cannot completely deny the
existence of other mtDNA mutations in the four LBWN





Figure 4 COX IV staining of the glomeruli and tubules. A: In the glome
B. In the tubules of a normal control, the tubular cells at the same luminal
one podocyte (arrow) expresses more COX IV than the other podocytes. D
detected (arrows). Only a part of tubular cells express extremely intense CO
the glomeruli of LBW 4, only one podocyte (arrow) expresses more COX IV
IV in a part of tubular lumens exhibits a mosaic pattern. The GSECs should
portion of podocytes (arrows) express more COX IV than the other podocy
stained (arrows) compared with the other cells in the same lumen. These cmtDNA mutations has previously been documented [8].
In addition, this method of detecting mtDNA mutations
using blood, urine sediment and kidney sections was able
to clearly detect the 3243 A >G mtDNA mutation in
patient Mt 1. This report also provides a new strategy for
detecting mtDNA mutations in nephropathy patients
carrying mtDNA mutations using urine samples. This
method is based on the observation that urine sediment
consists of certain components derived from podocytes
and/or tubular cells.
Why do patients with LBWN exhibit similar patho-
logical changes to those observed in nephropathy patients
with mtDNA mutations? It appears that the mitochondrial
function of podocytes is involved in the formation of FSGS
lesions, as we and others also recently proposed [17-21].
Although we cannot exactly evaluate the degree of foot
process effacement by the limitation of sampling, mild
foot process effacement were observed all our cases of
LBWN. In the present study, we did not observe any in-
crements in the number of mitochondria in the podocytes
of the patients with LBWN, which is indeed a different





ruli of a normal control, the podocytes almost equally express COX IV.
level almost equally express COX IV. C. In the glomeruli of LBW 1, only
. In the tubules of LBW 1, unbalanced strong staining for COX IV is
X IV compared with other tubular cells at the same luminal level. E: In
than the other podocytes. F. In the tubules of LBW 4, staining for COX
express intense COX IV staining (arrows). G: In the glomeruli of Mt 1, a
tes. H: In the tubules of Mt 1, a portion of tubular cells are intensely
ells should coincide with GSECs002E.
Table 2 Summary of the findings of nephropathy in the mitochondrial cytopathy and LBW-related nephropathy
patients
Normal Mitochondrial cytopathy LBW-related nephropathy
mtDNA mutation No Yes No
FSGS lesion No Yes1 Yes
Glomerular hypertrophy No Yes or No Yes
Foot process effacement No Yes Yes
Increased mitochondria in podocyte No Yes No
GSECs in tubules No Yes Yes
COX IV expression in glomeruli uniform mosaic pattern weak (but intense in a few podocytes)
COX IV expression in tubules uniform partially mosaic pattern partially mosaic pattern
1Although the two patients with mitochondrial cytopathy had no FSGS lesions in the glomeruli, the presence of FSGS lesions is a characteristic glomerular change
in mitochondrial cytopathy patients, as reported in many previous reports.
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dria is only one phenomenon underlying mitochondrial
abnormalities and is easily detected pathologically. In
fact, mitochondrial biogenesis is controlled by complex
mechanisms [22]; therefore, we cannot deny the possi-
bility of mitochondrial dysfunction in LBWN patients,
even when an increased number of mitochondria is not
observed. COX IV is one of the major components of
complex IV, the last enzyme in the respiratory electron
transport chain in mitochondria [23]. When we stained
the kidney sections using anti-COX-IV antibodies, the
staining intensity of podocytes and tubular cells ay the
same luminal levels were uniform. However, in patients
with mtDNA mutations, COX IV expression, which was
mainly expressed by podocytes in glomeruli, showed
mosaic patterns. Furthermore, a part of tubular cells
with mtDNA mutations extremely expressed COX IV
compared with other tubular cells at the same luminal
levels (Figure 4). COX IV expression was not uniform
in glomeruli of LBWN patients, too. A few podocytes
expressed stronger COX IV compared with most of
other podocytes. Only a part of tubular cells in LBWN
patients expressed extremely intense COX IV as like
those in patients with mtDNA mutations (Figure 4). Al-
though we cannot judge whether an unbalanced COX
IV expression directly affects the pathogenesis of kidney
disease, our results suggest the possibility that the mito-
chondrial function, not mitochondrial DNA mutations,
is associated with the etiopathogenesis of low birth
weight-related nephropathy.
In addition, GSECs could be occasionally observed in
aged patients. Therefore, GSECs might not be specific
findings. However, because all of LBWN patients had
GSECs in a part of their tubular cells, we think that
GSECs in LBWN should be “meaningful” pathological
changes. Furthermore, if GSECs are observed, especially
in young patients, the analysis of mtDNA might be
needed [24]. Now, we cannot explain why GSECs par-
tially appear. Furthermore, it is obscure that a part oftubular cells show intense COX IV expression although
most of tubular cells uniformly express COX IV at the
same luminal levels. Although we now hypothesize that
unbalance between high energy demand and low energy
supply might result in mitochondrial dysfunction, fur-
ther studies must be needed.
We cannot exclude the possibility that our four
patients with LBWN had similar pathological lesions to
those observed in the patients with mitochondrial cyto-
pathy “by chance”. In spite of these limitations, some
specific cases with characteristic pathological findings
should provide new aspects [25-27]. This report provides
new clues regarding mitochondria to prompt investiga-
tions of the pathomechanisms underlying the renal dys-
function associated with LBW.
Conclusion
This is the first report to show the pathological similar-
ities not only in glomeruli but also tubuli between
nephropathy with a LBW history and nephropathy with
mitochondrial cytopathy.
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